Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Aug 27

PMID 34445342

Citations 11

Authors

Yi-An Chen

Cheng-Hsiu Lu

Chien-Chih Ke

Sain-Jhih Chiu

Chi-Wei Chang

Bang-Hung Yang

Juri G Gelovani

Ren-Shyan Liu

Affiliations

Soon will be listed here.

Abstract

Epigenetic regulation by histone deacetylase (HDAC) is associated with synaptic plasticity and memory formation, and its aberrant expression has been linked to cognitive disorders, including Alzheimer's disease (AD). This study aimed to investigate the role of class IIa HDAC expression in AD and monitor it in vivo using a novel radiotracer, 6-(tri-fluoroacetamido)-1-hexanoicanilide ([F]TFAHA). A human neural cell culture model with familial AD (FAD) mutations was established and used for in vitro assays. Positron emission tomography (PET) imaging with [F]TFAHA was performed in a 3xTg AD mouse model for in vivo evaluation. The results showed a significant increase in HDAC4 expression in response to amyloid-β (Aβ) deposition in the cell model. Moreover, treatment with an HDAC4 selective inhibitor significantly upregulated the expression of neuronal memory-/synaptic plasticity-related genes. In [F]TFAHA-PET imaging, whole brain or regional uptake was significantly higher in 3xTg AD mice compared with WT mice at 8 and 11 months of age. Our study demonstrated a correlation between class IIa HDACs and Aβs, the therapeutic benefit of a selective inhibitor, and the potential of using [F]TFAHA as an epigenetic radiotracer for AD, which might facilitate the development of AD-related neuroimaging approaches and therapies.

Citing Articles

Epigenetics in Neurodegenerative Diseases.

van Zundert B, Montecino M Subcell Biochem. 2025; 108():73-109.

PMID: 39820861 DOI: 10.1007/978-3-031-75980-2_3.

Oxyresveratrol-β-cyclodextrin mitigates streptozotocin-induced Alzheimer's model cognitive impairment, histone deacetylase activity in rats: in silico & in vivo studies.

Agarwal T, Manandhar S, B H, Famurewa A, Gurram P, Suggala R Sci Rep. 2024; 14(1):9897.

PMID: 38688962 PMC: 11061296. DOI: 10.1038/s41598-024-57188-7.

Relationship Between Reactive Astrocytes, by [F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer's Disease.

Kong Y, Maschio C, Shi X, Xie F, Zuo C, Konietzko U Mol Neurobiol. 2024; 61(10):8387-8401.

PMID: 38502413 PMC: 11415417. DOI: 10.1007/s12035-024-04106-7.

Deciphering the roles of subcellular distribution and interactions involving the MEF2 binding region, the ankyrin repeat binding motif and the catalytic site of HDAC4 in Drosophila neuronal morphogenesis.

Tan W, Hawley H, Wilson S, Fitzsimons H BMC Biol. 2024; 22(1):2.

PMID: 38167120 PMC: 10763444. DOI: 10.1186/s12915-023-01800-1.

Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy.

Nohesara S, Mostafavi Abdolmaleky H, Thiagalingam S, Zhou J Epigenomics. 2023; 16(1):57-77.

PMID: 38088063 PMC: 10804213. DOI: 10.2217/epi-2023-0342.

References

Verdin E, Dequiedt F, Kasler H . Class II histone deacetylases: versatile regulators. Trends Genet. 2003; 19(5):286-93. DOI: 10.1016/S0168-9525(03)00073-8. View

Stine W, Jungbauer L, Yu C, LaDu M . Preparing synthetic Aβ in different aggregation states. Methods Mol Biol. 2010; 670:13-32. PMC: 3752843. DOI: 10.1007/978-1-60761-744-0_2. View

She A, Kurtser I, Reis S, Hennig K, Lai J, Lang A . Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia. Cell Chem Biol. 2017; 24(7):892-906.e5. PMC: 5695697. DOI: 10.1016/j.chembiol.2017.06.010. View

Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L . HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 2013; 11(11):e1001717. PMC: 3841096. DOI: 10.1371/journal.pbio.1001717. View

Meng Q, Li F, Jiang S, Li Z . Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases. ACS Med Chem Lett. 2014; 4(9):858-62. PMC: 4027442. DOI: 10.1021/ml400191z. View

Risacher S, Saykin A . Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol. 2013; 9:621-48. PMC: 3955298. DOI: 10.1146/annurev-clinpsy-050212-185535. View

Hendricks J, Keliher E, Marinelli B, Reiner T, Weissleder R, Mazitschek R . In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem. 2011; 54(15):5576-82. PMC: 3150598. DOI: 10.1021/jm200620f. View

Laws M, Bonomi R, Kamal S, Gelovani D, Llaniguez J, Potukutchi S . Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [F]TFAHA. Sci Rep. 2019; 9(1):3595. PMC: 6401080. DOI: 10.1038/s41598-019-40054-2. View

Lang C, Campbell K, Ryan B, Carling P, Attar M, Vowles J . Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. Cell Stem Cell. 2018; 24(1):93-106.e6. PMC: 6327112. DOI: 10.1016/j.stem.2018.10.023. View

10.

Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R . Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39(3):409-21. DOI: 10.1016/s0896-6273(03)00434-3. View

11.

Shen X, Chen J, Li J, Kofler J, Herrup K . Neurons in Vulnerable Regions of the Alzheimer's Disease Brain Display Reduced ATM Signaling. eNeuro. 2016; 3(1). PMC: 4770009. DOI: 10.1523/ENEURO.0124-15.2016. View

12.

Raymond E, Dalgleish A, Damber J, Smith M, Pili R . Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2013; 73(1):1-8. PMC: 3889691. DOI: 10.1007/s00280-013-2321-8. View

13.

Perutz M . Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 1999; 24(2):58-63. DOI: 10.1016/s0968-0004(98)01350-4. View

14.

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

15.

Couto P, Millis R . PET Imaging of Epigenetic Influences on Alzheimer's Disease. Int J Alzheimers Dis. 2015; 2015:575078. PMC: 4633540. DOI: 10.1155/2015/575078. View

16.

Lahm A, Paolini C, Pallaoro M, Nardi M, Jones P, Neddermann P . Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A. 2007; 104(44):17335-40. PMC: 2077257. DOI: 10.1073/pnas.0706487104. View

17.

Wang Y, Huang Z, Yuan M, Jing F, Cai R, Zou Q . Role of Hypoxia Inducible Factor-1α in Alzheimer's Disease. J Alzheimers Dis. 2021; 80(3):949-961. DOI: 10.3233/JAD-201448. View

18.

Zhu Y, Huang M, Bushong E, Phan S, Uytiepo M, Beutter E . Class IIa HDACs regulate learning and memory through dynamic experience-dependent repression of transcription. Nat Commun. 2019; 10(1):3469. PMC: 6677776. DOI: 10.1038/s41467-019-11409-0. View

19.

Guo L, Han A, Bates D, Cao J, Chen L . Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains. Proc Natl Acad Sci U S A. 2007; 104(11):4297-302. PMC: 1838596. DOI: 10.1073/pnas.0608041104. View

20.

Airaksinen M, TAMMISTO T . Toxic actions of the metabolites of halothane: LD 50 and some metabolic effects of trifluoroethanol and trifluoroacetic acid in mice and guinea pigs. Ann Med Exp Biol Fenn. 1968; 46(2):242-8. View